Abstract
Systemic sclerosis (SSc) is a complex, heterogeneous autoimmune connective tissue disease. Autologous hematopoietic stem-cell transplantation (AHSCT) has emerged as a valuable treatment option for rapidly progressive diffuse cutaneous SSc (dcSSc) patients, and thus far is the only treatment that has been shown to have a long-term clinical benefit. AHSCT is thought to reintroduce immune homeostasis through elimination of pathogenic self-reactive immune cells and reconstitution of a new, tolerant immune system. However, the mechanism of action underlying this reset to tolerance remains largely unknown. In this study we review the immune mechanisms underlying AHSCT for SSc, with a focus on the role of the innate immune cells, including monocytes and natural killer (NK) cells, in restoring immune balance after AHSCT.
Original language | English |
---|---|
Pages (from-to) | 34-39 |
Number of pages | 6 |
Journal | Clinical and Experimental Immunology |
Volume | 201 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jul 2020 |
Keywords
- autologous hematopoietic stem-cell transplantation
- diffuse cutaneous systemic sclerosis
- immunological tolerance
- innate immunity
- Autografts
- Killer Cells, Natural/immunology
- Monocytes/immunology
- Humans
- Hematopoietic Stem Cell Transplantation
- Scleroderma, Systemic/immunology
- Immunity, Innate